Impacts of CD152 polymorphisms on cervical cancer susceptibility

The objective of this study was to discuss the effect of CD152 polymorphisms rs231775, rs3087243 and rs5742909 on the susceptibility to cervical cancer.

The databases of PubMed, EMBASE, Cochrane Library, ISI Web of Science, Google Scholar Web, CNKI and Wanfang were searched for eligible studies. Chi-square-based Q test examined heterogeneity between included studies, and when P_{heterogeneity} was less than 0.05, random-effect model was used to calculate odds ratios (ORs) with their 95 % confidence intervals (95 % CIs); or else, fixed-effect model was selected. Sensitivity analysis was implemented to determine the stability of final results through removing enrolled studies one at a time and then re-obtaining overall estimates. Publication bias among included studies was checked employing Begg's funnel plot and Egger's test.

CD152 polymorphism rs231775 decreased cervical cancer risk in total analysis under the genetic models of GG vs. AA, GG vs. AA + AG and G vs. A (OR = 0.73, 95 % CI = 0.59-0.91; OR = 0.78, 95 % CI = 0.65-0.94; OR = 0.92, 95 % CI = 0.87-0.98), and so did the polymorphism rs3087243 in total analysis under the comparisons of AA vs. GG, AA + GA vs. GG, AA vs. GG + GA, A vs. G and GA vs. GG (OR = 0.51, 95 % CI = 0.42-0.60; OR = 0.71, 95 % CI = 0.62-0.82; OR = 0.57, 95 % CI = 0.50-0.66; OR = 0.70, 95 % CI = 0.64-0.77; OR = 0.83, 95 % CI = 0.72-0.97). Besides, the polymorphism rs5742909 elevated the disease onset in total analysis under the contrasts of TT vs. CC, TT + CT vs. CC, TT vs. CC + CT, T vs. C and CT vs. CC (OR = 2.66, 95 % CI = 1.75-4.04; OR = 1.54, 95 % CI = 1.24-1.91; OR = 2.13, 95 % CI = 1.12-4.03; OR = 1.44, 95 % CI = 1.17-1.78; OR = 1.49, 95 % CI = 1.22-1.83).

CD152 polymorphisms rs231775 and rs3087243 significantly decrease the risk of cervical cancer, while rs5742909 may increase the disease risk.